Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy

Eur J Clin Pharmacol. 2013 Apr;69(4):1037-9. doi: 10.1007/s00228-012-1414-3. Epub 2012 Oct 3.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Flecainide / administration & dosage
  • Flecainide / therapeutic use*
  • Humans
  • Male
  • Mutation*
  • Myotonia Congenita / drug therapy*
  • Myotonia Congenita / genetics
  • NAV1.4 Voltage-Gated Sodium Channel / genetics*
  • Nuclear Family
  • Pharmacogenetics
  • Treatment Outcome
  • Voltage-Gated Sodium Channel Blockers / administration & dosage
  • Voltage-Gated Sodium Channel Blockers / therapeutic use*

Substances

  • NAV1.4 Voltage-Gated Sodium Channel
  • Voltage-Gated Sodium Channel Blockers
  • Flecainide

Supplementary concepts

  • Potassium aggravated myotonia